Treatment with dupilumab reduced severe asthma attacks and improved the lung condition of children significantly.  Recent international trials of the drug, conducted by the Vanderbilt University Medical Center, a medical provider with multiple hospitals in the US, found very promising results with the drug as it reduced severe asthma attacks and improved the lung condition of children aged 6-11. The trial, titled VOYAGE, was published in the New England Journal of Medicine, and analysed 408 children with uncontrolled type-2 inflammation asthma and found that the exacerbations reduced by nearly 60%. The researchers said that the drug was not effective for children who did not have type 2 inflammation, adding that the phase 3 trial established the safety and efficacy of the drug.